Page 69 - GPD-3-3

Gene & Protein in Disease Amino acid metabolism in neurodegeneration

of ALS. Neurology. 2019;92:e1868-e1877. Petrusewicz I, Kwieciński H. Anti-neural antibodies in
serum and cerebrospinal fluid of amyotrophic lateral
doi: 10.1212/WNL.0000000000007311
sclerosis (ALS) patients. Acta Neurol Scand. 1999;100:
84. Lee J, Ryu H, Kowall NW. Motor neuronal protection by 238-243.
L-arginine prolongs survival of mutant Sod1 (G93A) ALS doi: 10.1111/j.1600-0404.1999.tb0038.x
mice. Biochem Biophys Res Commun. 2009;384:524-529.
88. Fiszman ML, Ricart KC, Latini A, Rodríguez G, Sica REP.
doi: 10.1016/j.bbrc.2009.05.015 In vitro neurotoxic properties and excitatory amino acids
85. Kh C, Cn L, Cm C, et al. Altered metabolic profiles of concentration in the cerebrospinal fluid of amyotrophic
the plasma of patients with amyotrophic lateral sclerosis. lateral sclerosis patients. Relationship with the degree
Biomedicines. 2021;9(12):1944. of certainty of disease diagnoses. Acta Neurol Scand.
2010;121:120-126.
doi: 10.3390/biomedicines9121944
doi: 10.1111/j.1600-0404.2009.01200.x
86. Lanznaster D, de Assis DR, Corcia P, Pradat PF, Blasco H.
Metabolomics biomarkers: A strategy toward therapeutics 89. Granatiero V, Sayles NM, Savino AM, et al. Modulation
improvement in ALS. Front Neurol. 2018;9:1126. of the IGF1R-MTOR pathway attenuates motor neuron
toxicity of human ALS SOD1G93A astrocytes. Autophagy.
doi: 10.3389/fneur.2018.01126 2021;17:4029-4042.
87. Niebroj-Dobosz I, Jamrozik Z, Janik P, Hausmanowa- doi: 10.1080/15548627.2021.1899682

Volume 3 Issue 3 (2024) 15 doi: 10.36922/gpd.3294